Work

A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.9076

Authors: Ryan J. Sullivan, Nageatte Ibrahim, Donald P. Lawrence, Julie Aldridge, F. Stephen Hodi, Keith Flaherty, Christine Conley, Sarah DeNoble, James Walter Mier, Daniel C. Cho, Michael B. Atkins, David F. McDermott

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Harvard University, Beth Israel Deaconess Medical Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3012475914

Cites:

Cited by: 3

Related to: 10